10-Q: Hinge Health Q3 2025: Revenue Up 53%, Net Loss Widens

Hinge Health, Inc. reports a 53% revenue increase for Q3 2025, reaching $154.2 million, alongside a significant widening of net loss to $560.4 million for the nine months ended September 30, 2025, primarily due to IPO-related stock-based compensation.

Summary

• Revenue for the three months ended September 30, 2025, increased by $53.6 million, or 53%, to $154.2 million compared to $100.6 million in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, increased by $144.0 million, or 53%, to $417.1 million compared to $273.1 million in the same period of 2024.
• Net loss for the three months ended September 30, 2025, was $(1.8) million, compared to net income of $0.3 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, significantly widened to $(560.4) million, compared to $(39.0) million in the prior year period, primarily due to $625.8 million in stock-based compensation expense related to IPO vesting.
• Gross profit for the three months ended September 30, 2025, increased by $46.9 million, or 59%, to $126.2 million, with gross margin improving to 82% from 79%.
• Gross profit for the nine months ended September 30, 2025, increased by $120.4 million, or 59%, to $324.2 million, with gross margin improving to 78% from 75%.
• Total operating expenses for the nine months ended September 30, 2025, surged to $897.8 million from $256.6 million in 2024, largely driven by the stock-based compensation expense.
• The number of clients grew by 25% year-over-year to 2,560 as of September 30, 2025, from 2,047 as of September 30, 2024.
• Last Twelve Months (LTM) calculated billings increased by 50% to $624.2 million as of September 30, 2025, from $416.9 million as of September 30, 2024.
• Cash and cash equivalents were $261.3 million as of September 30, 2025, a decrease from $300.8 million as of December 31, 2024.
• Net cash provided by operating activities was $107.5 million for the nine months ended September 30, 2025, a substantial increase from $10.7 million in the same period of 2024.
• The company completed its Initial Public Offering (IPO) in May 2025, receiving aggregate net proceeds of $255.7 million, primarily used to pay employee taxes for restricted stock unit (RSU) and performance-based restricted stock unit (PRSU) settlements.
• An acquisition of certain assets of a privately held company for approximately $4.0 million in February 2025 resulted in a $2.5 million increase in goodwill.

Sentiment

Score: 4

Explanation: While the company shows strong revenue growth and improved gross margins, the substantial net loss for the nine months, largely due to IPO-related stock-based compensation, and a significant accumulated deficit indicate ongoing unprofitability. The cash position decreased, and the company faces numerous risks in a highly regulated and competitive evolving market. The IPO was a significant event, but its immediate financial impact (large stock-based compensation) overshadows operational improvements, leading to a neutral-to-slightly-negative sentiment.

Positives

• Strong revenue growth of 53% for both the three and nine months ended September 30, 2025, driven by existing clients and an expanding client base.
• Improved gross margin to 82% in Q3 2025 (up from 79%) and 78% for the nine months (up from 75%), indicating increased operational efficiencies in care team and supply chain.
• Significant client base expansion, with 2,560 clients as of September 30, 2025, representing a 25% period-over-period growth.
• Robust growth in Last Twelve Months (LTM) calculated billings, increasing by 50% to $624.2 million as of September 30, 2025.
• Substantial increase in net cash provided by operating activities to $107.5 million for the nine months ended September 30, 2025, compared to $10.7 million in the prior year.
• Successful completion of an Initial Public Offering (IPO) in May 2025, raising $255.7 million in net proceeds.
• High 12-month client retention rate of 98% as of December 31, 2024.
• Continued innovation and development of the platform, including AI-powered motion tracking technology (TrueMotion), the Enso device, and HingeConnect.

Negatives

• Significant net loss of $(560.4) million for the nine months ended September 30, 2025, a substantial increase from $(39.0) million in the prior year, primarily due to IPO-related stock-based compensation expense.
• Accumulated deficit of $1.1 billion as of September 30, 2025, indicating a history of unprofitability.
• Massive increases in operating expenses (Research and development up 327%, Sales and marketing up 96%, General and administrative up 555% for nine months) largely driven by non-cash stock-based compensation expense.
• Cash and cash equivalents decreased by $39.4 million from December 31, 2024, to September 30, 2025.
• Net cash used in investing activities was $(76.1) million for the nine months ended September 30, 2025.
• Net cash used in financing activities was $(70.9) million for the nine months ended September 30, 2025, primarily due to employee tax payments on RSU/PRSU settlements and the repurchase of Series E preferred stock.

Risks

• A history of net losses, anticipated increasing expenses, and uncertainty regarding achieving or maintaining profitability.
• Challenges in effectively managing rapid growth, which could hinder business plan execution and competitive response.
• Potential inability to successfully execute growth initiatives, business strategies, or operating plans, especially with expansion into new markets like fully-insured health plans and Medicare Advantage populations.
• A limited operating history makes it difficult to evaluate the business, future prospects, and predict future results of operations.
• Fluctuations in results of operations on a quarterly and annual basis, potentially leading to stock price volatility if analyst or investor expectations are not met.
• Inability to attract new clients, non-renewal of existing client agreements, less favorable renewal terms, or failure to achieve performance guarantees.
• Failure to retain existing members or add new members, which could materially adversely affect revenue.
• Substantial reliance on a limited number of health plans and partners for client relationships; disruption or loss of these relationships could be detrimental.
• Increasing reliance on AI and machine learning technologies exposes the company to risks including development challenges, regulatory uncertainties, and potential third-party claims.
• Inability to establish, maintain, protect, and enforce intellectual property and proprietary rights, or potential claims of infringement from third parties.
• Operating in a highly regulated industry with evolving laws and regulations, leading to increased compliance costs and liabilities.
• Exposure to federal, state, and foreign healthcare fraud and abuse laws and regulations; non-compliance could have a material adverse effect.
• Legislative or regulatory healthcare reform measures may make business operations more difficult or costly.
• The Enso device is subject to extensive government regulation, with risks of delays or failure in obtaining necessary marketing authorizations or certifications for modifications or new devices.
• The FDA may modify its enforcement policies for medical software products, potentially subjecting programs to extensive regulatory requirements.
• Volatility in the price of Class A common stock, which may decline regardless of operating performance.
• The dual class common stock structure concentrates voting control with Founders and Series E preferred stockholders, limiting other stockholders' influence.
• Defects, errors, or vulnerabilities in the platform and programs could harm reputation and business.
• Proprietary technology and solutions may not operate properly, leading to claims or diversion of resources.
• Dependence on information technology systems and third-party vendors; failures, disruptions, or data loss could expose the company to liability.
• Actual or perceived failures to comply with data protection, privacy, security, advertising, and consumer protection laws.
• Failure to comply with applicable data interoperability and information blocking rules.
• Failure to comply with obligations under license or technology agreements with third parties.
• Reliance on third-party and open-source software; inability to obtain licenses or errors in such software.
• Reliance on internet infrastructure and bandwidth providers; failures could negatively impact relationships.
• Legal challenges to the ability to offer the platform and programs in certain jurisdictions due to varying state laws.
• Evolving government laws and regulation of the internet; unfavorable changes could substantially harm the business.
• Changes or developments in U.S. health insurance markets, including single-payer proposals, could adversely harm the business.
• Potential for medical liability claims, which could incur significant expenses not fully covered by insurance.
• Subject to regular and special audit requirements, as well as inquiries or investigations by governmental agencies.
• Medical device products may cause or contribute to adverse events or be subject to failures/malfunctions requiring FDA reporting.
• Misuse or off-label use of medical device products could harm reputation or lead to liability.
• Legislative or regulatory reforms in the U.S. and foreign countries may make it more difficult and costly to obtain marketing authorizations for medical devices.
• Medical device products must be manufactured in accordance with applicable laws and regulations; failure could lead to recalls or production termination.
• Fluctuations in tax obligations and effective tax rate.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited by Section 382/383 of the Code.
• Changes in accounting principles and standards related to variable interest entities could have an adverse effect.
• Uncertainty regarding sales, use, and other tax laws or regulations.
• International operations subject to exchange rate fluctuations and other currency risks.
• No intention to pay dividends for the foreseeable future.
• Sales of substantial amounts of Class A common stock by existing security holders may cause price decline.
• Anti-takeover provisions could impair takeover attempts.
• Claims for indemnification by directors and officers may reduce available funds.
• Exclusive forum provisions in organizational documents may limit stockholders' ability to bring claims.
• Estimates of market opportunity and forecasts of market growth may be inaccurate.
• Uncertain or unfavorable conditions in the industry or global economy could limit growth.
• Business operations subject to interruption by natural disasters, power shortages, and other events beyond control.
• Insurance strategy may not be adequate to protect from all business risks.
• Management has limited experience in operating a public company.
• Significant additional costs and regulations as a public company.
• Failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting.
• Compliance with reduced reporting and disclosure requirements as an emerging growth company may make Class A common stock less attractive to investors.

Future Outlook

The company anticipates increasing expenses in the foreseeable future as it invests in business growth, client and member retention, partner engagement, hiring, and platform development. Seasonality in calculated billings is expected to continue, with highest billings in the second quarter and lowest free cash flow in the first quarter. The market for digital musculoskeletal (MSK) care is considered to be in its early stages, and the company intends to continue investing for long-term growth. Opportunities for expansion beyond current markets into additional government agencies and programs like Medicare and Medicaid are being explored. Global expansion is also planned, which will incur additional costs for program development and compliance with international regulations. Increased legal, accounting, and other expenses are expected due to operating as a public company, and cash balances are projected to increase with business growth.

Management Comments

• Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care.
• We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation.
• We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy.
• We believe that we grow efficiently because of our scalable, repeatable go-to-market model.
• Our software-led, AI-powered delivery model not only aims to provide a better experience for our members and a less expensive alternative for our clients, but also allows us to innovate and continuously improve our platform.
• We believe our business is resilient even in difficult macroeconomic conditions given our focus on delivering positive outcomes for our members and ROI for our clients.
• In tougher economic periods, our business continued to see substantial growth as cost management became an even higher priority for clients.
• Our cost base is mostly variable, and we maintain strong operational focus with efficiency improvement targets for every function within the company.

Industry Context

The digital health market is characterized as new, unproven, and rapidly evolving, with continuous changes in technology, regulatory requirements, and consumer demands. The musculoskeletal (MSK) market, including care and medical devices, is also in a nascent and rapidly developing stage. The U.S. healthcare industry is undergoing significant structural changes, marked by ongoing national debates on health insurance systems, including proposals for single-payer or government-run programs. There is increasing regulatory scrutiny on AI and machine learning technologies in healthcare, with new laws and regulations being considered or enacted across federal, state, and international jurisdictions (e.g., California, Colorado, Utah, Texas, EU AI Act, UK GDPR). Competition in digital MSK care involves both established enterprise companies and smaller point solution providers, with a potential for larger entities to develop their own in-house solutions.

Corporate Governance

Legal Proceedings

• Not subject to any pending or threatened litigation, individually or in the aggregate, for which it is reasonably possible to have a material effect on consolidated financial position or results of operations as of September 30, 2025, and December 31, 2024.
• May be involved in various legal proceedings or subject to claims and investigations in the ordinary course of business from time to time.
• Future litigation may be necessary to defend against third-party proprietary rights claims, establish own proprietary rights, or for other matters, which could be costly and divert management attention.

Related Party Transactions

• On February 4, 2025, the Executive Chairman repaid in full a partial recourse promissory note in the amount of $2.2 million.
• On February 7, 2025, the Chief Executive Officer repaid in full a partial recourse promissory note in the amount of $2.2 million.
• On February 26, 2025, the former Chief Financial Officer repaid in full a partial recourse promissory note in the amount of $0.5 million.
• The company engages the law firm of Perkins Coie LLP for various legal services, incurring fees of $1.1 million for the nine months ended September 30, 2025, compared to $0.8 million for the same period in 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity raises, concentrated voting control with Class B and Series E preferred stockholders, market price volatility, no expected dividends, and potential for stock price decline from sales by existing security holders.
• Employees: Experienced a workforce reduction of approximately 160 people (10%) in April 2024, recognized significant stock-based compensation expense due to IPO-related vesting, and new incentive plans (2025 Incentive Award Plan and ESPP) were adopted.
• Clients: Benefit from cost reductions in MSK care and positive member outcomes, but are subject to performance guarantees and potential changes in pricing models (e.g., engagement-based).
• Members: Gain access to an AI-powered MSK care platform, wearable devices, and expert clinicians, but face potential risks of harm/injury from medical device products or platform errors, and rely on high-quality support.
• Partners (Health Plans, PBMs, TPAs): Crucial for client acquisition and revenue generation, but relationships are non-exclusive and terminable, with potential for renegotiation of terms or referral to competitors.
• Creditors: Any future debt financing could involve restrictive covenants affecting the company's financial and operational flexibility.

Next Steps

• Continue to invest additional funds to grow the business, maintain and increase members and clients, expand engagement with partners, hire additional employees, develop new programs, and enhance the platform.
• Expand into new markets beyond self-insured and fully-insured employers, Medicare Advantage, and federal insurance plans, including additional government agencies and programs such as Medicare and Medicaid.
• Continue global expansion, incurring additional costs to develop global programs and address international regulations.
• Evaluate the impact of new accounting guidance (ASU No. 2025-06, ASU No. 2025-05, ASU No. 2024-04, ASU No. 2024-03, ASU No. 2023-09).
• Continue to assess and address the impact of the One Big Beautiful Bill Act (OBBBA) and related guidance.
• Continuously monitor compliance with laws in every jurisdiction, especially regarding remote healthcare and physical therapy.
• Respond to the FDA's request for information regarding the marketing of TrueMotion technology.
• Management team will devote substantial attention to transitioning to interacting with public company analysts and investors and complying with public company laws.

Key Dates

Recommendation

Hinge Health demonstrates strong revenue growth and improved gross margins, indicating operational efficiency and market demand for its digital MSK solutions. The successful IPO and increased client base are positive indicators. However, the substantial net loss for the nine months, primarily due to IPO-related stock-based compensation, raises concerns about sustainable profitability. The company operates in a highly competitive and rapidly evolving regulatory environment, particularly concerning AI and medical devices, which presents significant risks. The dual-class share structure also concentrates voting power, which may be a deterrent for some investors. Given the strong growth but also the significant unprofitability and regulatory uncertainties, a 'Hold' recommendation is appropriate for a seasoned investor to monitor the company's path to sustainable profitability and successful navigation of regulatory and competitive challenges.

Keywords

Digital Health, Musculoskeletal (MSK) Care, Telehealth, AI-powered Healthcare, Wearable Devices, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Stock-based Compensation, IPO, Client Growth, Operating Expenses, Risk Factors, Corporate Governance, Medical Device Regulation, Data Privacy, Healthcare Technology, Employer-sponsored Healthcare